PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.00%
Revenue growth of 7.00% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
3.45%
Gross profit growth of 3.45% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
-12.72%
Negative EBIT growth while Medical - Pharmaceuticals median is -0.52%. Seth Klarman would check if external or internal factors caused the decline.
-11.49%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
44.66%
Net income growth of 44.66% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
44.66%
EPS growth of 44.66% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
44.66%
Diluted EPS growth of 44.66% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.07%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 22.19%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
-13.38%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
32.50%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 17.88%. Joel Greenblatt might see a short-term competitive advantage at play.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
141.27%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 2.50% over a decade. Joel Greenblatt might see a standout compounder of earnings.
37.60%
Net income/share CAGR of 37.60% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
124.28%
3Y net income/share CAGR of 124.28% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a small advantage that can be scaled further.
132.72%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 35.51% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
27.89%
5Y equity/share CAGR 75-90% of Medical - Pharmaceuticals median. John Neff calls for higher returns or more efficient buybacks to match peers.
71.06%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 29.72%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
-25.00%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
2.27%
5Y dividend/share CAGR of 2.27% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
-25.00%
Dividend reductions while Medical - Pharmaceuticals median grows. Seth Klarman sees a near-term disadvantage if peers maintain or raise payouts.
-37.14%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
3.40%
Inventory growth of 3.40% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
8.47%
Asset growth of 8.47% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
6.41%
BV/share growth of 6.41% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
25.46%
Debt growth of 25.46% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-42.69%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.